Free tool
FAERS Monitor: Sotyktu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214958 or its brand name (Sotyktu, Deucravacitinib). Reports on generic versions are filed under their own applications.
Reports
2,976
Serious
619
21% of reports
Hospitalization
163
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective286
- acne255
- pruritus244
- rash206
- psoriasis190
- erythema171
- off label use120
- skin burning sensation88
- product dose omission issue83
- adverse event82
- headache82
- pain79
- mouth ulceration76
- folliculitis67
- diarrhoea62
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 140 |
| 2023 | 1,053 |
| 2024 | 850 |
| 2025 | 579 |
| 2026 | 352 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,183 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 67 | 45.4 | 35.8 | 2,851 |
| mouth ulcerationSignal | 76 | 25.6 | 20.5 | 1,766 |
| acneSignal | 255 | 23.8 | 21.2 | 5,560 |
| psoriasisSignal | 190 | 10.3 | 9.0 | 1,593 |
| skin burning sensationSignal | 88 | 8.7 | 7.1 | 593 |
| adverse eventSignal | 82 | 6.3 | 5.1 | 361 |
| erythemaSignal | 171 | 5.9 | 5.1 | 694 |
| pruritusSignal | 244 | 4.5 | 4.0 | 670 |
| rashSignal | 206 | 3.3 | 2.9 | 343 |
| product dose omission issue | 83 | 2.0 | 1.6 | 41 |
| drug ineffective | 286 | 1.5 | 1.4 | 56 |
| off label use | 120 | 1.0 | 0.8 | 0 |
| headache | 82 | 0.9 | 0.7 | 0 |
| pain | 79 | 0.9 | 0.7 | 1 |
| diarrhoea | 62 | 0.7 | 0.5 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.